Title:
BTK INHIBITOR, PHARMACEUTICALLY ACCEPTABLE SALT, POLYMORPH AND APPLICATION THEREOF
Document Type and Number:
WIPO Patent Application WO/2020/187267
Kind Code:
A1
Abstract:
The present invention provides a BTK inhibitor, a pharmaceutically acceptable salt, a polymorph and an application thereof. Specifically, the present invention provides (R)-6-((1-Acryloylpiperidin-3-yl)amino)-7-fluoro-4-((2-fluoro-4-morpholinophenyl)amino)-1,2-dihydro-3H-pyrrolo[3,4-c]pyridin-3-one, or the polymorph of a pharmaceutically acceptable salt thereof, and an application thereof. In addition, the present invention further discloses a pharmaceutical composition comprising the inhibitor and an application thereof.
Inventors:
JIANG TAOTAO (CN)
LI JINJING (CN)
ZHAO SHUANGNI (CN)
YAO XIA (CN)
LI JINJING (CN)
ZHAO SHUANGNI (CN)
YAO XIA (CN)
Application Number:
PCT/CN2020/080024
Publication Date:
September 24, 2020
Filing Date:
March 18, 2020
Export Citation:
Assignee:
SHANGHAI HAIYAN PHARMACEUTICAL TECH CO LTD (CN)
YANGTZE RIVER PHARM GROUP CO (CN)
YANGTZE RIVER PHARM GROUP CO (CN)
International Classes:
C07D471/04; A61K31/437; A61P35/00
Domestic Patent References:
| WO2019062329A1 | 2019-04-04 |
Other References:
J W MULLENS: "Crystallization", 1993, BUTTERWORTH-HEINEMAN LTD.
See also references of EP 3851438A4
See also references of EP 3851438A4
Attorney, Agent or Firm:
ADVANCE CHINA IP LAW OFFICE (CN)
Download PDF:
Previous Patent: WEARABLE DEVICE, SIGNAL PROCESSING METHOD AND DEVICE
Next Patent: FUSION PROTEIN FOR ENHANCING GENE EDITING AND USE THEREOF
Next Patent: FUSION PROTEIN FOR ENHANCING GENE EDITING AND USE THEREOF